Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.
Having recently neutralised Erleada, Pfizer moves to challenge earlier use of Zytiga.
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
Reata's unexpected success in kidney disease could see Abbvie paying out yet more licensing cash.
Pivotal data on Astrazeneca’s lupus project anifrolumab are due, while Astellas and Pfizer await a US approval decision on Xtandi.
Japanese group prefers M&A over license